Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.02.009 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Christina C Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Electronic address: christina.huang@duke.edu. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Mediastinal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Consolidation radiation therapy (RT) is often recommended in diffuse large B-cell lymphoma. The current recommended dose of 30 Gy was established in the pre-rituximab and PET-CT era. We hypothesized that following a complete response to modern systemic therapy, as determined by PET-CT, a lower dose of RT would be equally effective. METHODS AND MATERIALS: Patients with diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma achieving a complete response by PET-CT (Deauville score 1-3) after ≥4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin were eligible. Consolidation RT dose was 19.5-20 Gy. The primary endpoint of the original study was 5-year freedom from local recurrence. RESULTS: From 2010 to 2016, 62 patients were enrolled. The stage distribution was as follows: I-II (n = 49, 79%) and III-IV (n = 13, 21%). Bulky disease (≥7.5 cm) was present in 24 patients (39%). Most (n = 58, 94%) received rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Four cycles were administered to 34% of patients, whereas 66% received 5-6 cycles. A median follow-up was 9 years. Overall, 1 patient experienced local recurrence with freedom from local recurrence of 98% at both 5 and 10 years (95% CI, 88%-99%). Seven patients progressed outside of the RT field. Progression-free survival and overall survival at 10 years were 77% (95% CI, 62%-87%) and 80% (95% CI, 64%-89%), respectively. CONCLUSIONS: Long-term results of this phase 2 study, with a median follow-up of 9 years, did not demonstrate late local failures when patients received ∼20 Gy consolidation RT. A larger (n = 240) confirmatory study from the International Lymphoma Radiation Oncology Group evaluating ∼20 Gy of RT after ≥3 cycles of chemoimmunotherapy completed accrual in 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Electronic address: christina.huang@duke.edu.
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
- Department of Medicine, Division of Medical Oncology, University of North Carolina Medical Center, Chapel Hill, North Carolina.
Zitieren
APA
Huang, C. C., Wan, Z., Niedzwiecki, D., Prosnitz, L. R., Beaven, A. W., & Kelsey, C. R. (2025). Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.02.009
Vancouver
Huang CC, Wan Z, Niedzwiecki D, Prosnitz LR, Beaven AW, Kelsey CR. Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.02.009
BibTeX
@article{Huang2025,
author = {Huang, Christina C and Wan, Zihan and Niedzwiecki, Donna and Prosnitz, Leonard R and Beaven, Anne W and Kelsey, Chris R},
title = {Long-term Update of a Phase 2 Study of Dose-Reduced Radiation in Diffuse Large B-Cell Lymphoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.02.009}
}
EUVIMED